Drug Profile
Doxorubicin GA3
Alternative Names: DOX GA3Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Mar 1999 A preclinical study has been added to the pharmacodynamics and the pharmacokinetics sections
- 03 Mar 1999 New profile
- 03 Mar 1999 Preclinical development for Cancer in Netherlands (Unknown route)